Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

摘要: The oxazaphosphorine analog ifosfamide (IFO) has demonstrated an increased therapeutic index in a variety of solid tumors and hematologic malignancies compared with its parent compound cyclophosphamide. A fractionated dose schedule over 5 days as continuous infusion combination the uroprotective agent sodium-2-mercapto-ethane-sulfonate (mesna) is considered to provide improved therapeutic/toxic ratio. Stability data IFO demonstrate long-term stability for use disposable pumps outpatient treatment. In all, 52 patients various were entered feasibility study receive IFO. All required have subcutaneous venous port system implanted. following drug combinations used: single agent, IFO/mitoxantrone, IFO/carboplatinum/etoposide, IFO/etoposide/MTX, IFO/epirubicin. Mitoxantrone epirubicin given together Starting was between 1.6–2.0 g/m2/day×5 absence major or peripheral toxicitiy. Mesna at 50% that calculated No renal, bladder central nervous toxicity observed. 247 courses only few technical complications due improper handling documented.